We would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, July 31, 2026, on review and recommendation of Audit Committee of the Company, ....

CONCORD BIOTECH LIMITED B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat. Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440 Email ID: complianceofficer@concordbiotech.com -------------------------------------------------------------------------------------------------------------------------------------------- July 31, 2026 To To The Manager, Listing Department General Manager, Listing Department National Stock Exchange of India Limited BSE Limited Plot No. C/1 G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East), Dalal Street, Mumbai -400 051 Mumbai – 400 001 Symbol: CONCORDBIO Scrip Code: 543960 Sub.: Outcome of Board Meeting held today i.e. Friday, July 31, 2026 - Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) as amended from time to time. Dear Sir/ Ma’am, With reference to the intimation of Board meeting submitted on July 28, 2026, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, July 31, 2026, on review and recommendation of Audit Committee of the Company, has inter-alia considered and approved, the unaudited Standalone and Consolidated Financial Results for the first quarter ended on June 30, 2026. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the unaudited Standalone and Consolidated Financial Results of the Company for the first quarter ended on June 30, 2026, along with the Limited Review Report issued by M/s. BSR & Co. LLP, the Statutory Auditors. The Board Meeting commenced at 03:30 P.M. and concluded at 4:35 P.M. This is for your information and records. For Concord Biotech Limited Paritosh Trivedi Company Secretary and Compliance Officer ACS 63623 Encl : As above ------------------------------------------------------------------------------------------------------------------------------------------ Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225. (India) Phone : +91-2714-222604, 398200 Fax : +91-2714-222504 Website : www.concordbiotech.com 903 Commerce House V BSR& Co. LLP Near Vodafone House, Prahaladnagar Corporate Road, Ahmedabad 380 051 Chartered Accountants India Telephone: +91 (79) 7145 0001 Fax: +91 (79) 7145 0050 Limited Review Report on unaudited consolidated financial results of Concord Biotech Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, amended To the Board of Directors of Concord Biotech Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Concord Biotech Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its joint venture for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). 2 This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scopе than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4 The Statement includes the results of the entities mentioned in Annexure I to the Statement. 5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit. 6 Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. SR& Co. LL P Anmedabad n a U T rtered Accou Registered Office BSR&Co (a partnersnip firm with Registration No ЗA61223) converted into BSR & Co 14th Floor. Central 3 Wing and ving. Nesco Il Park 4. Nesco mited Liability Partnersnip with LLP Registration No AAB-8-81) with effect from October 14 2013 estern Express Hignway. Goregaon (East). Mumbai 4000 Page 1 of 3 BSR& Co. LLP Limited Review Report (Continued) Concord Biotech Limited 7. We did not review the interim financial information of two Subsidiaries included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 26.86 Lakhs, total net loss after tax (before consolidation adjustments) of Rs. 7.69 Lakhs and total comprehensive loss (before consolidation adjustments) of Rs. 7.69 Lakhs, for the quarter ended 30 June 2026, as considered in the Statement. These interim financial information have been reviewed by other auditor whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion is not modified in respect of this matter. 8. The Statement includes the interim financial information of one Subsidiary which has not been reviewed, whose interim financial information reflect total revenues (before consolidation adjustments) of Rs. 7.59 Lakhs, total net loss after tax (before consolidation adjustments) of Rs. 331.73 Lakhs and total comprehensive loss (before consolidation adjustments) of Rs. 330.86 Lakhs, for the quarter ended 30 June 2026, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of Rs. 6.26 Lakhs and total comprehensive income of Rs. 6.26 Lakhs, for the quarter ended [Showing first 8,000 characters — download PDF for full document]